Floatz logo

TCR .ALPHA..BETA. (RECEPTOR), ANTI-(HUMAN P53 (PROTEIN)) (SYNTHETIC HUMAN SINGLE-CHAIN PRECURSOR) FUSION PROTEIN WITH INTERLEUKIN 2 (HUMAN)

Urethra Cancer

Altor BioScienceprotein_peptidePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

16 Active assets in the Urethra Cancer cohort.

Asset / SponsorPhaseRating
Carboplatin
Jonsson Comprehensive Cancer Center
Phase 2BB
Vinflunine
Dr Anders Ullén
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
Jonsson Comprehensive Cancer Center
Phase 1/2B
Nivolumab
M.D. Anderson Cancer Center
Phase 2B
Sorafenib
Dr Anders Ullén
Phase 2B

View all 30 →

Same molecule, other indications

TCR .ALPHA..BETA. (RECEPTOR), ANTI-(HUMAN P53 (PROTEIN)) (SYNTHETIC HUMAN SINGLE-CHAIN PRECURSOR) FUSION PROTEIN WITH INTERLEUKIN 2 (HUMAN) is also rated in:

obesity disorderDormant
CCC
Indicative ·
53 / 100
View asset →
bladder transitional cell carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
malignant renal pelvis neoplasmDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →